{"nctId":"NCT01197378","briefTitle":"Long-Term Safety Follow-up Study of Cysteamine Bitartrate Delayed-release Capsules (RP103)","startDateStruct":{"date":"2010-08-27","type":"ACTUAL"},"conditions":["Cystinosis"],"count":60,"armGroups":[{"label":"Cysteamine Bitartrate","type":"EXPERIMENTAL","interventionNames":["Drug: Cysteamine Bitartrate Delayed-release Capsules"]}],"interventions":[{"name":"Cysteamine Bitartrate Delayed-release Capsules","otherNames":["RP103","PROCYSBI®"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male and female subjects must have completed the last visit of Study RP103-03 and be willing to continue with RP103 treatment.\n\nOR for patients who did not complete the RP103-03 study:\n\n* Male and female subjects must have cystinosis.\n* Subjects must be on a stable dose of Cystagon® at least 21 days prior to Screening.\n* Within the last 6 months, no clinically significant change from normal in liver function tests (i.e., alanine aminotransferase \\[ALT\\], aspartate aminotransferase \\[AST\\], total bilirubin) and renal function (i.e., estimated glomerular filtration rate \\[eGFR\\]) at Screening as determined by the Investigator.\n* Subjects with an eGFR corrected for body surface area \\> 30 mL/min/1.73m².\n* Sexually active female subjects of childbearing potential (i.e., not surgically sterile \\[tubal ligation, hysterectomy, or bilateral oophorectomy\\] or at least 2 years naturally postmenopausal) must agree to utilize the same acceptable form of contraception from Screening through completion of the study.\n* Subjects must be willing and able to comply with the study restrictions and requirements.\n* Subjects or their parent or guardian must provide written informed consent and assent (where applicable) prior to participation in the study.\n\nExclusion Criteria:\n\n* Patients enrolled in the previous Study RP103-03 who did not complete their last scheduled Study visit or who do not wish to continue on treatment with RP103.\n\nAND for patients who did not complete the RP103-03 study:\n\n* Subjects less than 1 year old\n* Subjects with a known history, currently of the following conditions or other health issues that make it, in the opinion of the investigator, unsafe for them to participate: inflammatory bowel disease (if currently active) or have had prior resection of small intestine; Heart disease (e.g., myocardial infarction, heart failure, unstable arrhythmias or poorly controlled hypertension) 90 days prior to Screening; Active bleeding disorder 90 days prior to Screening; Malignant disease within the last 2 years.\n* Patients with a hemoglobin level \\< 10 g/dL at Screening or a level that, in the opinion of the investigator, makes it unsafe for the subject to participate.\n* Subjects with known hypersensitivity to cysteamine or penicillamine.\n* Female subjects who are nursing, planning a pregnancy, known or suspected to be pregnant, or have a positive serum pregnancy screen.\n* Subjects who, in the opinion of the Investigator, are not able or willing to comply with the protocol.","healthyVolunteers":false,"sex":"ALL","minimumAge":"1 Year","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Treatment-emergent Adverse Events","description":"Drug-related adverse events (AEs) are AEs the investigator assessed as having relation to drug of 'possibly', 'probably' or 'definitely'.\n\nThe severity of AEs was categorized according to the Common Terminology Criteria for Adverse Events (CTCAE), Version 3.0 as follows:\n\n* Mild (Grade 1): experience is minor and does not cause significant discomfort to subject or change in activities of daily living (ADL); subject is aware of symptoms but symptoms are easily tolerated;\n* Moderate (Grade 2): experience is an inconvenience or concern to the subject and causes interference with ADL, but the subject is able to continue with ADL.\n* Severe (Grade 3): experience significantly interferes with ADL and the subject is incapacitated and/or unable to continue with ADL\n* Life-threatening (Grade 4): experience that, in the view of the Investigator, places the subject at immediate risk of death from the event as it occurred.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"58","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"37","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"32","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Trough Plasma Cysteamine Concentration","description":"Plasma cysteamine concentration was determined using methods employing Hydrophilic Interaction Liquid Chromatography (HILC) high pressure liquid chromatography (HPLC) tandem mass spectrometry (HPLC-MS/MS).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.17","spread":"0.093"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.29","spread":"0.613"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.37","spread":"0.513"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.48","spread":"0.718"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.36","spread":"0.412"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.34","spread":"0.659"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.47","spread":"0.708"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.40","spread":"0.399"}]}]}]},{"type":"SECONDARY","title":"White Blood Cell Cystine Concentration","description":"White blood cell (WBC) cystine concentration was determined using high performance liquid chromatography-electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.68","spread":"1.275"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.93","spread":"1.174"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.65","spread":"0.569"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.75","spread":"0.852"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.65","spread":"0.851"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.66","spread":"0.575"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.38","spread":"1.672"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.17","spread":"2.117"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":32,"n":59},"commonTop":["Vomiting","Headache","Diarrhoea","Nausea","Influenza"]}}}